Evidence map›Paper›PMID 42587178›Full record

ArticleNature cancer2026

TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia.

Qiwei Wang, Jingyi Li, Xin Zeng, Lina Liu, Huan Lu, Yin Zhao, Yan Huang, Rui Wang, Chen Wang, Yingli Han and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Qiwei Wang *Bone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China. qiwei921@zju.edu.cn.ORCID http://orcid.org/0000-0001-9197-3163
Jingyi Li *Bone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Xin Zeng *Bone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Lina Liu *Bone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Huan Lu *Bone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Yin ZhaoBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Yan HuangSchool of Clinical Medicine, Chengdu Medical College, Chengdu, China.
Rui WangBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Chen WangBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Yingli HanBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Yishan YeBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Yanmin ZhaoBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Jimin ShiBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Yi LuoBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Weiyan ZhengBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Yongxian HuBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China.
Shibing WangZhejiang Key Laboratory of Zero Magnetic Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
Xiangmin TongZhejiang Key Laboratory of Zero Magnetic Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China. tongxiangmin@163.com.ORCID http://orcid.org/0000-0002-4175-0321
He HuangBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China. huanghe@zju.edu.cn.ORCID http://orcid.org/0000-0002-2723-1621
Shanshan PeiBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China. shanshan.pei@zju.edu.cn.ORCID http://orcid.org/0000-0001-9619-2614
Pengxu QianBone Marrow Transplantation Center of the First Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Liangzhu Laboratory, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangzhou, China. axu@zju.edu.cn.ORCID http://orcid.org/0000-0001-5636-6704

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) remains challenging, especially for older or unfit individuals who develop resistance to venetoclax (VEN)-based regimens. Although TIM3 represents a promising AML target, clinical blockade has yielded suboptimal outcomes. Here, we develop VINCENT (VEN-integrated natural killer cell engager targeting TIM3), a therapeutic platform combining anti-CD16 and anti-TIM3 antibodies with nanoformulated VEN. In VEN-resistant AML cell lines and patient-derived xenograft models, VINCENT overcomes resistance by enhancing VEN delivery, eliminating TIM3

Identifiers

PMID42587178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.